Peptable

Comparison

BPC-157 vs CJC-1295

Function

While BPC-157 is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects111, CJC-1295 is used in research to chronically elevate endogenous growth hormone and IGF-1 levels, enabling studies of body composition, metabolic, and anti-aging effects of prolonged GH exposure10.

Mechanism

While BPC-157 works as a synthetic 15-amino-acid fragment of a gastric cytoprotective protein that promotes angiogenesis and tissue protection primarily by modulating VEGFR2 signaling, Src/caveolin-1–dependent eNOS activation, and nitric oxide production111, CJC-1295 is a tetrasubstituted 29-amino-acid analog of GHRH(1–29) that acts as a potent agonist at the GHRH receptor and, in its DAC form, covalently binds serum albumin to extend half-life from minutes to days, resulting in sustained pulsatile GH and IGF-1 increase1082.

Receptor

BPC-157

VEGFR2 (vascular endothelial growth factor receptor 2) on endothelial cells, with downstream eNOS and nitric-oxide–mediated signaling11

CJC-1295

Growth hormone–releasing hormone receptor (GHRHR) on anterior pituitary somatotrophs1094103

Organism or Origin

BPC-157

Synthetic peptide derived from a naturally occurring human gastric 'Body Protection Compound' isolated from human gastric juice111

CJC-1295

Synthetic peptide based on human hypothalamic GHRH10120

Gene

BPC-157

Not assigned in the current dataset.

CJC-1295

GHRH

Summary

BPC-157 and CJC-1295 are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: BPC-157 is more often discussed in the realm of Gastroenterology, Musculoskeletal health, and Dermatology and aesthetics, whereas CJC-1295 is more often associated with the realm of Metabolic and endocrine and Aging and longevity. Their biological logic is quite different: BPC-157 is a signaling modulator, whereas CJC-1295 is a receptor agonist and a hormone analog. Both are synthetic in origin and both are still best understood as being in Preclinical development. BPC-157 takes the form of a linear peptide, whereas CJC-1295 is closer to a peptide conjugate, CJC-1295 incorporates d-amino acid substitution features that are not part of BPC-157; while their sequence patterns also diverge, with BPC-157 showing proline-rich features and CJC-1295 showing alpha-helical domain features.

Sources

11BPC-157 - Wikipedia, https://en.wikipedia.org/wiki/BPC-157
10CJC-1295: Long-Acting GHRH Analog - Alpha Carbon Labs, https://alphacarbonlabs.com/blog/cjc-1295-long-acting-ghrh-analog
82CJC-1295 no DAC 5mg (Mod GRF 1-29), https://www.peptidesciences.com/mod-grf-1-29-5mg-cjc-1295-no-dac
94Growth-hormone-releasing hormone receptor - Wikipedia, https://en.wikipedia.org/wiki/Growth-hormone-releasing_hormone_receptor
103Growth-hormone-releasing hormone receptor - Wikipedia, https://en.wikipedia.org/wiki/Growth_hormone_releasing_hormone_receptor
120Growth hormone–releasing hormone - Wikipedia, https://en.wikipedia.org/wiki/Growth_hormone%E2%80%93releasing_hormone